Ironwood Pharmaceuticals (IRWD) EBT (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of EBT data on file, last reported at $65.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 279.68% year-over-year to $65.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 91.81% YoY), and the FY2025 full-year result was -$91.1 million, down 154.54% from the prior year.
• EBT improved to $65.2 million in Q1 2026, from -$160.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $125.9 million in Q4 2024 to a low of -$1.1 billion in Q2 2023.
• A 5-year average of -$45.9 million and a median of $37.8 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 2100.97% in 2023 and surged 291.62% in 2025, its largest moves.
• Tracing IRWD's EBT over 5 years: stood at $72.3 million in 2022, then tumbled by 371.46% to -$196.2 million in 2023, then jumped by 164.17% to $125.9 million in 2024, then tumbled by 227.65% to -$160.7 million in 2025, then jumped by 140.56% to $65.2 million in 2026.
• Business Quant data shows IRWD's EBT at $65.2 million in Q1 2026, -$160.7 million in Q4 2025, and $68.0 million in Q3 2025.